PATENT CLAIM ANALYSIS

Application Number: 15996151
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["514", "248000"]

Abstract:
The present disclosure relates to bifunctional compounds, which find utility as modulators of c-Met and/or p38 (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

Claim (Index 25):
The composition of  claim 24 , wherein the additional bioactive agent is anti-cancer agent.

Metadata:
- Claim Count in Document: 34.0
- Percentile: 94.0
- Lexical Diversity: 1.83333
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15881318', '14822309', '15341275', '15730728', '15847628']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.810961688129635
- 35 USC 102 Novelty (BERT): 0.595411134630805
- Combined Prediction Score: 0.789406632779752
- Mean Citation Score: 439.84440000000006
- Max Citation Score: 695.188
- Similarity Product: 412.7755407402515

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test